CurrentCignaPolicy N/A

Cinacalcet Prior Authorization Policy

Defines Cigna's prior authorization criteria for coverage of cinacalcet (Sensipar and generic) for FDA‑approved and select supported indications, and who may prescribe/consult. Applies to health benefit plans administered by Cigna companies.

Policy Summary

PayerCigna

PolicyCinacalcet Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review DateMar 12, 2025

Key ActionObtain prior authorization and ensure the medication is prescribed by or in consultation with the appropriate specialist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Indications in overview

1 yrTypical approval duration

>=2x ULNBaseline iPTH

YesSpecialist required

Coverage Criteria for Cinacalcet (Sensipar)

Hypercalcemia due to Parathyroid Carcinoma (FDA‑approved)

Covered when ALL of the following are met

Parathyroid carcinoma: Cinacalcet is prescribed by or in consultation with an oncologist or endocrinologist.

Approve for 1 year if prescribed by or in consultation with an oncologist or endocrinologist.

Hypercalcemia with Primary Hyperparathyroidism (FDA‑approved)

Approve for 1 year if BOTH criteria A and B are met

Primary hyperparathyroidism criteria: A) Patient has failed or is unable to undergo parathyroidectomy due to a contraindication; AND B) Medication is prescribed by or in consultation with a nephrologist or endocrinologist.

Parathyroidectomy is the expected first-line therapy when patient is eligible; cinacalcet approved for 1 year when surgery is not possible.

Policy Summary

PayerCigna

PolicyCinacalcet Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review DateMar 12, 2025

Key ActionObtain prior authorization and ensure the medication is prescribed by or in consultation with the appropriate specialist.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Hyperparathyroidism in Post‑Renal Transplant Patients (other use with supportive evidence)

Approve for 1 year if BOTH of the following are met

Post‑transplant hyperparathyroidism: A) Baseline (prior to starting cinacalcet) calcium and intact parathyroid hormone (iPTH) levels are above the normal range, as defined by the laboratory reference values; AND B) Medication is prescribed by or in consultation with a transplant physician, nephrologist, or endocrinologist.

Not an FDA indication but approved as a supported use for 1 year when criteria are met.

Prescriber Requirements, Documentation, and Operational Notes

Prior Authorization

Prior Authorization and Specialist Prescriber Requirement

Prior authorization is required for cinacalcet. Approvals are provided for the durations noted in the policy and typically require the drug to be prescribed by or in consultation with a specialist (nephrologist, endocrinologist, oncologist, or transplant physician) depending on the indication.

Prior authorization required
Approvals issued for specified durations (see indications)
Specialist prescriber or documented specialist consultation generally required

Note

Surgery Expected Before Cinacalcet When Eligible

For primary hyperparathyroidism, parathyroidectomy is the expected first-line treatment. Cinacalcet will be approved only when the patient has failed or is unable to undergo parathyroidectomy due to a contraindication or is otherwise ineligible for surgery.

Parathyroidectomy is primary treatment for primary hyperparathyroidism
Cinacalcet approved only if surgery is contraindicated or patient is ineligible

Documentation Required

Required Baseline Labs

Documentation must include baseline laboratory values prior to initiating cinacalcet as specified by indication (for example, baseline iPTH measured on two occasions for secondary hyperparathyroidism; baseline calcium and iPTH for post-renal transplant hyperparathyroidism).

Secondary hyperparathyroidism: baseline iPTH ≥ 2× ULN measured on two separate occasions prior to starting therapy
Post-renal transplant hyperparathyroidism: baseline calcium and iPTH above laboratory normal range prior to starting therapy

Denial Risk

Not Covered Uses

Use of cinacalcet for any indication not listed as covered in this policy is considered experimental, investigational or unproven and is not covered. This includes use for primary hyperparathyroidism when the patient is eligible for parathyroidectomy (i.e., surgery candidacy without contraindication).

Not covered: any use not listed as covered
Not covered: primary hyperparathyroidism when patient is eligible for parathyroidectomy

Key Definitions

Secondary hyperparathyroidism — definition and clinical context (inv-14)

DefinitionSecondary hyperparathyroidism is a frequent complication of chronic kidney disease caused by reduced circulating calcitriol and disturbances in calcium and phosphorus metabolism leading to increased PTH, bone resorption, and marrow fibrosis.

PathophysiologyDisturbed mineral metabolism in CKD (low calcitriol, altered calcium/phosphorus) drives elevated PTH secretion

Clinical consequenceElevated PTH leads to osteoclastic bone resorption and marrow fibrosis; common in dialysis patients

Relation to cinacalcetIndication: cinacalcet is indicated to treat secondary hyperparathyroidism in adults on dialysis

Calcimimetic (cinacalcet) — definition and therapeutic role (inv-15)

DefinitionCalcimimetic (cinacalcet) is a calcium‑sensing receptor agonist that lowers parathyroid hormone (PTH)

Therapeutic roleUsed to treat hypercalcemia due to parathyroid carcinoma, primary hyperparathyroidism when surgery is not possible, and secondary hyperparathyroidism in adults on dialysis

LimitationNot indicated for CKD patients not on dialysis due to increased risk of hypocalcemia

Background on Cinacalcet and Indications

Cinacalcet is a calcimimetic (a calcium‑sensing receptor agonist) that lowers parathyroid hormone (PTH) levels by increasing the sensitivity of the calcium‑sensing receptor on parathyroid cells. It is indicated for treatment of hypercalcemia due to parathyroid carcinoma, hypercalcemia in primary hyperparathyroidism when parathyroidectomy is contraindicated or not feasible, and secondary hyperparathyroidism in adults with chronic kidney disease on dialysis. The agent is not indicated for patients with CKD who are not on dialysis because of an increased risk of hypocalcemia. Prior authorization is required and approvals are granted for specified durations (typically 1 year), with prescribing or consultation by an appropriate specialist (for example, endocrinology, nephrology, transplant surgery or oncology) as specified by indication.

OpenPayer

Cinacalcet Prior Authorization Policy

Coverage Criteria for Cinacalcet (Sensipar)

Covered Drugs and Key Diagnostic Thresholds

Prescriber Requirements, Documentation, and Operational Notes

Key Definitions

Background on Cinacalcet and Indications